| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 4/8/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +7.19% | +2.67% | - | - | 148M | ||
| +0.15% | +1.04% | +16.34% | +74.17% | 49.38B | ||
| +0.66% | +3.56% | +63.69% | +113.01% | 36.35B | ||
| +2.50% | +0.21% | -5.74% | +23.32% | 11.87B | ||
| -0.81% | -4.33% | +12.58% | +69.24% | 11.53B | ||
| +0.38% | -2.06% | +34.70% | +131.86% | 8.99B | ||
| +0.81% | +1.96% | +47.67% | -6.23% | 7B | ||
| -0.51% | -2.10% | +12.20% | +32.13% | 6.76B | ||
| -0.52% | -2.45% | +1.83% | +165.65% | 6.46B | ||
| -1.32% | -11.87% | -32.46% | -0.24% | 5.49B | ||
| Average | +0.90% | -0.95% | +16.76% | +66.99% | 15.98B | |
| Weighted average by Cap. | +0.38% | +0.32% | +26.15% | +78.38% |
Employees
2,191
Sector
Pharmaceuticals
















